nash
FDA approves first treatment for liver scarring due to fatty liver disease
March 15, 2024Medical Communications Endocrinology, FDA, fatty liver disease, liver scarring, nash
The US Food and Drug Administration (FDA) has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult …
Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA
September 14, 2023Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom
Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …
Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
June 8, 2023Medical Education Echosens, Hepatology, Inventiva, liver disease, nash, non-alcoholic steatohepatitis
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and …
Genfit’s NASH drug fails Phase 3 clinical trial
May 12, 2020Manufacturing and Production FDA, nash
The Phase 3 trial for Genfit’s drug elafibranor has failed to improve outcomes for patients with the fatty liver disease …
Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis
November 11, 2019Research and Development, Sales and Marketing Novartis, nash, non-alcoholic steatohepatitis, pharma
The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR …
Gilead’s selonsertib crashes at Phase 3 in NASH
April 26, 2019Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
February 20, 2019Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
Gilead shares drop 4% after failure of NASH drug to meet primary endpoint
February 12, 2019Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib
Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …
Roche’s Genentech to acquire inflammatory drug discovery firm Jecure
November 28, 2018Research and Development, Sales and Marketing Genentech, Jecure, Roche, liver disease, nash, pharma
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of …
Pfizer and Novartis partner up to develop combo therapies for NASH
October 29, 2018Research and Development, Sales and Marketing Novartis, Pfizer, liver, nash, pharma
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or …
Regeneron-Alnylam team up to treat NASH
March 22, 2018Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical
Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …
Galectin Therapeutics’ share value plummets by half after NASH drug failure
December 6, 2017Research and Development Galectin Therapeutics, nash, pharma, trial failure
Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis …
Top Ten most popular articles on Pharmafile.com this week
September 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten
It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …
Allergan posts disappointing data in NASH
September 25, 2017Research and Development, Sales and Marketing Allergan, biotech, drugs, nash, pharma, pharmaceutical
It was only last year that Allergan decided to cough up $1.7 billion to acquire Tobira Therapeutics, with the main …
Allergan and Novartis join forces to develop NASH combo therapy
April 18, 2017Manufacturing and Production, Research and Development Allergan, Novartis, nash
Allergan and Novartis have announced a new partnership to conduct a clinical trial in the treatment area of non-alcoholic steatohepatitis …
Latest content
FibroFind appoints Lee Borthwick as CEO
